Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 503 participants.
Also called NCT01582854
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 503 participants
- Sponsor
- Registry
-
NCT01582854 -
U1111-1132-3434
-
- Other papers using this trial's data
- ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belarus, Kazakhstan, Russia
- Registry status
- Completed
Technical summary
Registry record NCT01582854. Randomized; double masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2016-02-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
- Acronym
- ARTEMIDA
- Condition
- Post-Stroke Cognitive Impairment (PSCI)
- Intervention (Drug)
- Actovegin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01582854- Content hash
73732d731eb3cf22ae29ef4c1377d1b669f7fbea43699ac0b7aa1d069f2092d8